This article, by Kenneth Yood and Christine Cohn of Sheppard Mullin, presents a summary of some of the key features in Senator Baucus’ health care bill that are particularly relevant to the drug industry and that merit close attention.
Anyone doubting the commitment of business to compliance and ethics will be surprised by the findings of a survey by the SCCE and HCCA which reveals spending on compliance has remained stronger than anticipated. Roughly three out of four companies either kept compliance spending even or actually increased it in 2009, and for 2010 the prognosis is even brighter.
The Advanced Medical Technology Association recently publicly recognized early adopters of the revised AdvaMed Code of Ethics on Interactions with Health Care Professionals.
On Christmas Eve it was announced that Boston Scientific has agreed to pay $22 million as it settles claims that one of its divisions gave kickbacks to doctors.
A recent program sponsored by the Seton Hall Law Center for Health and Pharmaceutical Law & Policy urged health care and life sciences companies to place a high degree of emphasis on developing and maintaining effective corporate compliance programs.
Wendy Wysong, partner at Clifford Chance US LLP, discusses why health care providers should be critically reviewing their longstanding financial relationships to ensure compliance with recent revisions to the Stark and the Anti-Kickback laws.
Scott Bruns and Kathleen Meriwether of Ernst & Young count down the top five compliance risks facing life sciences companies, including sales & marketing risks, the FCPA and IFRS, as well as supply-chain integrity and aggregate spend.
Eric McClafferty, export compliance and international trade regulation partner at Kelley Drye & Warren LLP, examines important FCPA compliance and export compliance keys for health industry companies.
By Joel Hesch, Liberty University
The government has honed in on three primary areas where it alleges that a pharmaceutical company commits fraud. In addition, there is an emerging new area, adulterated products, where the DOJ is beginning to investigate and just may be the next huge compliance risk.
In today’s roundup, we offer links to the recent approval by Wyeth shareholders of the Pfizer takeover, corporate governance in times of crisis, and Andrew Cuomo’s intentions to sue Schwab for fraud over ARS.
